Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Eltrombopag in Chronic Myelomonocytic Leukemia (CMML) with Severe Thrombocytopenia: Final Results of a Multicenter Phase II Study

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-137469

Published: 2020

Journal Articles

A Randomized Phase II Study of Azacitidine (AZA) Alone or with Lenalidomide (LEN), Valproic Acid (VPA) or Idarubicin (IDA) in Higher-Risk MDS: Gfm's 'pick a Winner' Trial

Blood (2018) 132 (Supplement 1): 467.

https://doi.org/10.1182/blood-2018-99-111756

Published: 2018

Journal Articles

A Phase II Trial of Eltrombopag in Chronic Myelomonocytic Leukemia (CMML) with Thrombocytopenia

Raphael Itzykson, MD PhD, Jérôme Lambert, MDPhD, Daniela Barbieri, Berengere Gruson, Sylvain Thepot, MD, Thorsten Braun, MD PhD, Norbert Vey, Jacques Delaunay, MD, Laurence Legros, MD PhD, Julie Lejeune, Rosa Sapena, Nathalie Droin, Francoise Porteu, Eric Solary, MD, Pierre Fenaux, MD PhD

Blood (2017) 130 (Supplement 1): 4266.

https://doi.org/10.1182/blood.V130.Suppl_1.4266.4266

Published: 2017

Journal Articles

Targeted Sequencing for Clinical Investigation in Chronic Lymphocytic Leukemia

Damien Roos-Weil, Jérôme Lambert, MD PhD, Nathalie M. Droin, PhD, Frederik Damm, MD PhD, Romain Guieze, MD PhD, M'boypa Diop, Pierre Feugier, MD PhD, Stéphane Leprêtre, MD, Xavier Troussard, MD PhD, Vincent Ribrag, MD, Sandrine Vaudaux, Roselyne Delepine, Sophie Raynaud, MD, Julie Lejeune, Claude Lesty, Olivier A. Bernard, PhD, Florence Nguyen-Khac, MD PhD

Blood (2016) 128 (22): 3202.

https://doi.org/10.1182/blood.V128.22.3202.3202

Published: 2016

Journal Articles

Is Arsenic Trioxide (ATO) Required in the Treatment of High Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL2006) By the French Belgian Swiss APL Group

Blood (2016) 128 (22): 895.

https://doi.org/10.1182/blood.V128.22.895.895

Published: 2016

Journal Articles

Arsenic Trioxide (ATO) and ATRA with Limited Chemotherapy (CT) in Newly Diagnosed Standard Risk APL in the Elderly. a Report By the French Belgian Swiss APL Group (APL 2006 trial)

Lionel Ades, MD PhD, Xavier Thomas, MD PhD, Agnès Guerci, MD PhD, Arnaud Pigneux, MD, Norbert Vey, Emmanuel Raffoux, MD, Sylvie Castaigne, MD PhD, Olivier Spertini, Dominique Bron, MD PhD, Jean Pierre Marolleau, MD PhD, Gandhi Damaj, MD, Dominique Bordessoule, MD PhD, Julie Lejeune, Sylvie Chevret, Pierre Fenaux, MD PhD

Blood (2016) 128 (22): 898.

https://doi.org/10.1182/blood.V128.22.898.898

Published: 2016

Journal Articles

Mutational Analysis of MDS and AML Occurring after Treatment for Acute Promyelocytic Leukemia (APL). a Report of 9 Cases

Philippe Attias, Aline Renneville, MD, Xavier Thomas, MD PhD, Cecile Bally, Sandrine Hayette, Hassan Farhat, MD, Virginie Eclache, MD, Alice Marceau, Bruno Cassinat, PharmD, PhD, Jean Feuillard, MD PhD Pr, Christine Terré, PharmD, PhD, Eric Delabesse, PharmD, PhD, Sophie Park, MD PhD, Julie Lejeune, Sylvie Chevret, MD PhD, Lionel Ades, MD PhD, Claude Preudhomme, MD PhD, Pierre Fenaux, MD PhD

Blood (2016) 128 (22): 2861.

https://doi.org/10.1182/blood.V128.22.2861.2861

Published: 2016

Journal Articles

Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion

Virginie Chesnais, Aline Renneville, Andrea Toma, Jérôme Lambert, Marie Passet, Florent Dumont, Sylvie Chevret, Julie Lejeune, Anna Raimbault, Aspasia Stamatoullas, Christian Rose, Odile Beyne-Rauzy, Jacques Delaunay, Eric Solary, Pierre Fenaux, François Dreyfus, Claude Preudhomme, Olivier Kosmider, Michaela Fontenay

Blood (2016) 127 (6): 749–760.

https://doi.org/10.1182/blood-2015-04-640128

Published: 2016

Includes: Supplemental data

Journal Articles

The Gain of the Short Arm of Chromosome 2 (2p+) Induces XPO1 Overexpression and Drug Resistance in Chronic Lymphocytic Leukemia

Blood (2015) 126 (23): 492.

https://doi.org/10.1182/blood.V126.23.492.492

Published: 2015

Journal Articles

Is Arsenic Trioxide (ATO) Required in the Treatment of Standard Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL 2006) By the French Belgian Swiss APL Group

Blood (2015) 126 (23): 451.

https://doi.org/10.1182/blood.V126.23.451.451

Published: 2015

Journal Articles

Impact of NK Cell Reconstitution and Recipient HLA-C Typing on Clinical Outcome after Reduced Intensity Cord Blood Transplant: Results of a Prospective Phase II Multicentric Trial on Behalf of Societe Francaise De Greffe De Moelle Osseuse Et Therapie Cellulaire (SFGM-TC) and Eurocord

Blood (2015) 126 (23): 4393.

https://doi.org/10.1182/blood.V126.23.4393.4393

Published: 2015

Journal Articles

A Phase I-II Study of the Efficacy and Safety of Lenalidomide (LEN) Combined to Azacitidine (AZA) in Higher Risk MDS and AML with Del 5q - a Study By the Groupe Francophone Des Myelodysplasies (GFM)

Lionel Ades, MD PhD, Christian Récher, MDPhD, Julie Lejeune, Aspasia Stamatoullas, MD, Marie Sebert, MD, Jacques Delaunay, MD, Benedicte Samey, Krimo Bouabdallah, MD, Thorsten Braun, MD PhD, Norbert Vey, Sophie Park, MD PhD, Benoit de Renzis, Sylvie Chevret, Pierre Fenaux, MD PhD

Blood (2015) 126 (23): 2892.

https://doi.org/10.1182/blood.V126.23.2892.2892

Published: 2015

Journal Articles

A Phase II Add-on Study of Vorinostat (VOR) in Higher Risk Myelodysplastic Syndrome with Failure of Hypomethylating Agents (HMA): The GFM Azavor Study

Thomas Prebet, MD, Jacques Delaunay, MD, Eric Wattel, MDPhD, Thorsten Braun, MD PhD, Pascale Cony-Makhoul, MD, Sophie Dimicoli, MD, Stefan Wickenhauser, MD, Julie Lejeune, Sylvie Chevret, Fatiha Chermat, Pierre Fenaux, MD PhD, Norbert Vey

Blood (2015) 126 (23): 2900.

https://doi.org/10.1182/blood.V126.23.2900.2900

Published: 2015

Journal Articles

Can Assessment of Patient Monoclonal Immunoglobulins By Heavy/Light Analysis be Used to Assign Patient Responses Analogous to IMWG Response Criteria?

Eileen Boyle, Guillemette Fouquet, Julie Lejeune, Salomon Manier, MD, Lucile Musset, Claire Bories, Remy Dulery, MD, Stéphanie Guidez, Sarah Bonnet, Brigitte Onraed, Jean-Luc Faucompre, Sabine Tricot, Stephanie Poulain, Veronique Leblond, MD PhD, Kym Snell, Xavier Leleu, MD

Blood (2015) 126 (23): 3042.

https://doi.org/10.1182/blood.V126.23.3042.3042

Published: 2015

Journal Articles

Comparison of Waldenstrom Macroglobulinemia Responses Using Immunoglobulin Heavy / Light Chain Analysis and Conventional Electrophoresis Techniques

Eileen M Boyle, MD, Julie Lejeune, Salomon Manier, MD, Lucile Musset, MD, Claire Bories, MD, Remy Dulery, Stéphanie Guidez, Sarah Bonnet, MD, Guillemette Fouquet, MD, Brigitte Onraed, MD, Jean-Luc Faucompré, MD, Sabine Tricot, MD, Stephanie Poulain, Veronique Leblond, MD PhD, Xavier Leleu, MD, Stephen Harding, PhD

Blood (2014) 124 (21): 2978.

https://doi.org/10.1182/blood.V124.21.2978.2978

Published: 2014

Journal Articles

Phase II Trial In Advanced Waldenstrom Macroglobulinemia (WM) Patients With Bortezomib: Interest Of Addition Of Dexamethasone To Bortezomib On Behalf Of The French CLL/WM Intergroup (NCT 00777738)

Veronique Leblond, MD, Sylvie Chevret, marie Sarah Dilhuydy, Xavier Leleu, MD, PhD, Carole Soussain, MD, Stéphane Leprêtre, MD, Brigitte Dreyfus, Caroline Dartigeas, Beatrice Mahe, Bruno Anglaret, MD, Brigitte Pegourie, MD, Caroline Besson, MD, PhD, Therese Aurran, Anne Vekhoff, MD, Olivier Tournilhac, MD, PhD, Anne Banos, MD, Herve Oya, Julie Lejeune, Pierre Morel

Blood (2013) 122 (21): 4359.

https://doi.org/10.1182/blood.V122.21.4359.4359

Published: 2013

Journal Articles

Hevylite, a Novel M-Component Based Biomarkers of Response to Therapy and Survival in Waldenstrom Macroglobulinemia

Salomon Manier, MD, Julie Lejeune, Lucile Musset, MD, Eileen Boyle, MD, Remy Dulery, MD, Houria Debarri, MD, Jean-Luc Faucompret, Jordan Gauthier, MD, Claire Bories, MD, Guillemette Fouquet, MD, Charles Herbaux, MD, Sabine Tricot, MD, Annie Pietrantuono, MD, Frederic Combat, MD, Stephanie Poulain, MD, Stephen Harding, MD, PhD, Véronique Leblond, MD, PhD, Xavier Leleu, MD, PhD

Blood (2011) 118 (21): 2667.

https://doi.org/10.1182/blood.V118.21.2667.2667

Published: 2011

Journal Articles

International Phase III Study of Chlorambucil Versus Fludarabine As Initial Therapy for Waldenstrom's Macroglobulinemia and Related Disorders: Results in 414 Patients on Behalf of FCG CLL/ WM, GOELAMS, GELA, NCRI, ALLG

Veronique Leblond, Julie Lejeune, Olivier Tournilhac, MD, PhD, Pierre Morel, marie Sarah Dilhuydy, Caroline Dartigeas, Dr., Marion Malphette, Bruno Royer, John F. Seymour, MD, PhD, Sylvie Chevret, Steve Johnson, Roger G Owen, MD

Blood (2011) 118 (21): 776.

https://doi.org/10.1182/blood.V118.21.776.776

Published: 2011

Journal Articles

Gene Mutations and Minimal Residual Disease (MRD) As Predictors of Remission Duration in Adults with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Treated with High-Dose Cytarabine (HDAC) - First Results of the Prospective French Intergroup CBF-2006 Trial

Blood (2011) 118 (21): 410.

https://doi.org/10.1182/blood.V118.21.410.410

Published: 2011

Journal Articles

Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC

Blood (2011) 117 (23): 6109–6119.

https://doi.org/10.1182/blood-2010-11-317073

Published: 2011

NARROW

Eltrombopag in Chronic Myelomonocytic Leukemia (CMML) with Severe Thrombocytopenia: Final Results of a Multicenter Phase II Study

A Randomized Phase II Study of Azacitidine (AZA) Alone or with Lenalidomide (LEN), Valproic Acid (VPA) or Idarubicin (IDA) in Higher-Risk MDS: Gfm's 'pick a Winner' Trial

A Phase II Trial of Eltrombopag in Chronic Myelomonocytic Leukemia (CMML) with Thrombocytopenia

Targeted Sequencing for Clinical Investigation in Chronic Lymphocytic Leukemia

Is Arsenic Trioxide (ATO) Required in the Treatment of High Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL2006) By the French Belgian Swiss APL Group

Arsenic Trioxide (ATO) and ATRA with Limited Chemotherapy (CT) in Newly Diagnosed Standard Risk APL in the Elderly. a Report By the French Belgian Swiss APL Group (APL 2006 trial)

Mutational Analysis of MDS and AML Occurring after Treatment for Acute Promyelocytic Leukemia (APL). a Report of 9 Cases

Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion

The Gain of the Short Arm of Chromosome 2 (2p+) Induces XPO1 Overexpression and Drug Resistance in Chronic Lymphocytic Leukemia

Is Arsenic Trioxide (ATO) Required in the Treatment of Standard Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL 2006) By the French Belgian Swiss APL Group

Impact of NK Cell Reconstitution and Recipient HLA-C Typing on Clinical Outcome after Reduced Intensity Cord Blood Transplant: Results of a Prospective Phase II Multicentric Trial on Behalf of Societe Francaise De Greffe De Moelle Osseuse Et Therapie Cellulaire (SFGM-TC) and Eurocord

A Phase I-II Study of the Efficacy and Safety of Lenalidomide (LEN) Combined to Azacitidine (AZA) in Higher Risk MDS and AML with Del 5q - a Study By the Groupe Francophone Des Myelodysplasies (GFM)

A Phase II Add-on Study of Vorinostat (VOR) in Higher Risk Myelodysplastic Syndrome with Failure of Hypomethylating Agents (HMA): The GFM Azavor Study

Can Assessment of Patient Monoclonal Immunoglobulins By Heavy/Light Analysis be Used to Assign Patient Responses Analogous to IMWG Response Criteria?

Comparison of Waldenstrom Macroglobulinemia Responses Using Immunoglobulin Heavy / Light Chain Analysis and Conventional Electrophoresis Techniques

Phase II Trial In Advanced Waldenstrom Macroglobulinemia (WM) Patients With Bortezomib: Interest Of Addition Of Dexamethasone To Bortezomib On Behalf Of The French CLL/WM Intergroup (NCT 00777738)

Hevylite, a Novel M-Component Based Biomarkers of Response to Therapy and Survival in Waldenstrom Macroglobulinemia

International Phase III Study of Chlorambucil Versus Fludarabine As Initial Therapy for Waldenstrom's Macroglobulinemia and Related Disorders: Results in 414 Patients on Behalf of FCG CLL/ WM, GOELAMS, GELA, NCRI, ALLG

Gene Mutations and Minimal Residual Disease (MRD) As Predictors of Remission Duration in Adults with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Treated with High-Dose Cytarabine (HDAC) - First Results of the Prospective French Intergroup CBF-2006 Trial

Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only